Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines

scientific article published on 28 November 2012

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1007/S00535-012-0714-9
P932PMC publication ID3698425
P698PubMed publication ID23188091
P5875ResearchGate publication ID233788862

P50authorC Nelson HayesQ87781870
Kazuaki ChayamaQ87781872
Yoshiiku KawakamiQ114882129
P2093author name stringWaka Ohishi
P2860cites workGenetic variation in IL28B and spontaneous clearance of hepatitis C virusQ24596340
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine proteaseQ27473126
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A regionQ27478292
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsQ27487949
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.Q27690869
Global epidemiology of hepatitis C virus infectionQ27860799
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionQ27860901
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialQ27860949
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceQ28255243
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseQ29547886
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine ProteaseQ29614208
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyQ29614896
Telaprevir for retreatment of HCV infectionQ29619799
Telaprevir for previously untreated chronic hepatitis C virus infectionQ29619800
Course and outcome of hepatitis CQ29620057
The global burden of hepatitis CQ29620138
Natural history of chronic hepatitis CQ29620673
Preliminary study of two antiviral agents for hepatitis C genotype 1.Q34030288
Telaprevir for previously treated chronic HCV infectionQ34109057
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjectsQ34226129
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionQ34607097
Response-guided telaprevir combination treatment for hepatitis C virus infectionQ34632295
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis CQ35838595
American Gastroenterological Association technical review on the management of hepatitis C.Q36364156
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis CQ36371508
Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infectionQ36645372
Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.Q36670297
Hepatitis C virus: How genetic variability affects pathobiology of diseaseQ37825652
Hepatitis C virus resistance to protease inhibitorsQ37834102
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirinQ37972759
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patientsQ37980539
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric miceQ39807236
National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general populationQ40388576
Epidemiology of Hepatitis C in the WestQ40435898
Genetic heterogeneity of hepatitis C virus.Q40564932
Projecting future complications of chronic hepatitis C in the United StatesQ40594872
Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histologyQ42979944
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.Q42980375
Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loadsQ42982601
Telaprevir and peginterferon with or without ribavirin for chronic HCV infectionQ42987218
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.Q42993815
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized studyQ43032179
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholestQ43033968
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patientsQ43036643
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivoQ43037298
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevirQ43037585
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in JapanQ43039581
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsQ43039768
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null respondersQ43041150
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.Q43041414
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virusQ43042207
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in JapanQ43161784
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.Q44643929
Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.Q50558312
P433issue1
P921main subjectJapanQ17
peptideQ172847
mechanism of actionQ3271540
Hepatitis C virusQ708693
RNA virus infectious diseaseQ18967413
antiviral agentQ40207875
chronic hepatitis CQ55779873
chronic hepatitisQ62019625
P304page(s)1-12
P577publication date2012-11-28
2013-01-01
P1433published inJournal of GastroenterologyQ15764399
P1476titleTreatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines
P478volume48

Reverse relations

cites work (P2860)
Q43527241A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study
Q34513827A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors
Q42252352Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study
Q36689877Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study
Q50272981Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.
Q40060636Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.
Q41930211Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Q40964348Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.
Q37093573Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.
Q35078358HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study
Q37615658Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
Q40460374ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
Q40279001Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
Q42201546Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan
Q41161023MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection
Q40375437New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Q45846064Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.
Q42231673Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
Q38249065Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection
Q39675766Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Q35754227Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin
Q42247557Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Q37726632Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
Q38376454Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients
Q86103385Response to "treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'?"
Q42212457Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
Q41070380Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing
Q46085179Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
Q88495710The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan
Q43435689Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'?